Quantitative Blood Oxygenation Level Dependent (qBOLD) MR Imaging of Glioblastoma Multiforme for Assessment of Tumour Hypoxia.
Glioblastoma multiforme (GBM) is the most common primary malignant brain neoplasm in adults.
Despite recent diagnostic and therapeutic advances, including aggressive surgical resection
and chemoradiation, the prognosis of GBM has improved only slightly over the past two
decades, with median survival of approximately 15 months. Tumour hypoxia is a feature of GBM
that contributes to poor outcome through multiple mechanisms such as 1) overexpression of
enzymes that play roles in temozolomide resistance, the main chemotherapeutic agent in GBM
and 2) increase expression of cancer stem cells which are more resistant to radiation.
Hypoxic tumour regions are associated with higher rates of progression and recurrence.
In this study the investigators will use an advanced MRI technique called qBOLD to
non-invasively measure oxygenation in GBM and obtain targeted biopsies. The investigators
take advantage of physical characteristics of Ferumoxytol (Feraheme®) which is an iron
supplement, and utilize two recent technical advances not previously used in human tumours
to quantitatively measure oxygenation in GBM.
Prior knowledge of hypoxia can assist in prognostication and individualization of treatment
planning with special focus on hypoxic regions by targeted radiation dose or regimen
modulation; consideration of more intensive chemotherapy regimens; more aggressive and
targeted surgical resection and closer short-term clinical and imaging follow-ups.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society